메뉴 건너뛰기




Volumn 22, Issue 4, 2007, Pages 341-349

Current therapy for hepatitis C

Author keywords

Acute hepatitis C; Chronic hepatitis C; Therapy

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; SEROTONIN UPTAKE INHIBITOR; VALOPICITABINE; VIRUS RNA;

EID: 33847409707     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00384-005-0038-9     Document Type: Review
Times cited : (15)

References (60)
  • 3
    • 0032585237 scopus 로고    scopus 로고
    • Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)
    • Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J (1998) Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352:1426-1432
    • (1998) Lancet , vol.352 , pp. 1426-1432
    • Poynard, T.1    Marcellin, P.2    Lee, S.S.3    Niederau, C.4    Minuk, G.S.5    Ideo, G.6    Bain, V.7    Heathcote, J.8    Zeuzem, S.9    Trepo, C.10    Albrecht, J.11
  • 11
    • 13844270879 scopus 로고    scopus 로고
    • Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance
    • Santantonio T, Fasano M, Sinisi E, Guastadisegni A, Casalino C, Mazzola M, Francavilla R, Pastore G (2005) Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. Hepatology 42:329-333
    • (2005) Hepatology , vol.42 , pp. 329-333
    • Santantonio, T.1    Fasano, M.2    Sinisi, E.3    Guastadisegni, A.4    Casalino, C.5    Mazzola, M.6    Francavilla, R.7    Pastore, G.8
  • 13
  • 17
    • 4444339135 scopus 로고    scopus 로고
    • Standard treatment of acute and chronic hepatitis C
    • Zeuzem S (2004) Standard treatment of acute and chronic hepatitis C. Z Gastroenterol 42:714-719
    • (2004) Z Gastroenterol , vol.42 , pp. 714-719
    • Zeuzem, S.1
  • 18
    • 4444321892 scopus 로고    scopus 로고
    • Diagnosis, progression and therapy of hepatitis C virus infection as well as viral infection in children and adolescents - Results of an evidenced based consensus conference of the German Society for Alimentary Metabolic Disorders and in cooperation with the Hepatitis Competence Network
    • Fleig WE, Krummenerl P, Lesske J, Dienes HP, Zeuzem S, Schmiegel WH, Häussinger D, Burdelski M, Manns MP (2004) Diagnosis, progression and therapy of hepatitis C virus infection as well as viral infection in children and adolescents - results of an evidenced based consensus conference of the German Society for Alimentary Metabolic Disorders and in cooperation with the Hepatitis Competence Network. Z Gastroenterol 42:703-704
    • (2004) Z Gastroenterol , vol.42 , pp. 703-704
    • Fleig, W.E.1    Krummenerl, P.2    Lesske, J.3    Dienes, H.P.4    Zeuzem, S.5    Schmiegel, W.H.6    Häussinger, D.7    Burdelski, M.8    Manns, M.P.9
  • 19
    • 4444250494 scopus 로고    scopus 로고
    • Criteria for the definition of acute and chronic hepatitis C
    • Fleig WE, Krummener P, Lesske J (2004) Criteria for the definition of acute and chronic hepatitis C. Z Gastroenterol 42:707-713
    • (2004) Z Gastroenterol , vol.42 , pp. 707-713
    • Fleig, W.E.1    Krummener, P.2    Lesske, J.3
  • 20
    • 0036893172 scopus 로고    scopus 로고
    • National Institutes of Health consensus development conference statement: Management of hepatitis C: 2002 (June 10-12, 2002)
    • National Institutes of Health
    • National Institutes of Health (2002) National Institutes of Health consensus development conference statement: Management of hepatitis C: 2002 (June 10-12, 2002). Gastroenterology 123:2082-2099
    • (2002) Gastroenterology , vol.123 , pp. 2082-2099
  • 21
    • 0036829649 scopus 로고    scopus 로고
    • National Institutes of Health consensus development conference statement: Management of hepatitis C: 2002 (June 10-12, 2002)
    • National Institutes of Health
    • National Institutes of Health (2002) National Institutes of Health consensus development conference statement: Management of hepatitis C: 2002 (June 10-12, 2002). Hepatology 36:S3-S20
    • (2002) Hepatology , vol.36
  • 22
    • 9644262441 scopus 로고    scopus 로고
    • Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels
    • for the PEGASYS Study NR16071 Investigator Group
    • Zeuzem S, Diago M, Gane E, Reddy R, Pockros P, Prati D, Shiffman M, Farci P, Gitlin N, O'Brien C, Lamour F, Lardelli P, for the PEGASYS Study NR16071 Investigator Group (2004) Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 127:1724-1732
    • (2004) Gastroenterology , vol.127 , pp. 1724-1732
    • Zeuzem, S.1    Diago, M.2    Gane, E.3    Reddy, R.4    Pockros, P.5    Prati, D.6    Shiffman, M.7    Farci, P.8    Gitlin, N.9    O'Brien, C.10    Lamour, F.11    Lardelli, P.12
  • 23
    • 4444344991 scopus 로고    scopus 로고
    • Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD)
    • Reddy KR (2004) Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD). Semin Liver Dis 24(Suppl 2):33-38
    • (2004) Semin Liver Dis , vol.24 , Issue.SUPPL. 2 , pp. 33-38
    • Reddy, K.R.1
  • 24
    • 0041317671 scopus 로고    scopus 로고
    • Pharmacokinetics of peginterferons
    • Zeuzem S, Welsch C, Herrmann E (2003) Pharmacokinetics of peginterferons. Semin Liver Dis 23(Suppl 1):23-28
    • (2003) Semin Liver Dis , vol.23 , Issue.SUPPL. 1 , pp. 23-28
    • Zeuzem, S.1    Welsch, C.2    Herrmann, E.3
  • 25
    • 0037371144 scopus 로고    scopus 로고
    • Prediction of treatment outcome in patients with chronic hepatitis C: Significance of baseline parameters and viral dynamics during therapy
    • Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, Wiedenmann B, Hopf U, Zeuzem S (2003) Prediction of treatment outcome in patients with chronic hepatitis C: Significance of baseline parameters and viral dynamics during therapy. Hepatology 37:600-609
    • (2003) Hepatology , vol.37 , pp. 600-609
    • Berg, T.1    Sarrazin, C.2    Herrmann, E.3    Hinrichsen, H.4    Gerlach, T.5    Zachoval, R.6    Wiedenmann, B.7    Hopf, U.8    Zeuzem, S.9
  • 27
    • 0346727453 scopus 로고    scopus 로고
    • Optimized virologic response in hepatitis C virus genotype 4 with peginterferon-alpha2a and ribavirin
    • Diago M, Hassanein T, Rodes J, Ackrill AM, Sedarati F (2004) Optimized virologic response in hepatitis C virus genotype 4 with peginterferon-alpha2a and ribavirin. Ann Intern Med 140:72-73
    • (2004) Ann Intern Med , vol.140 , pp. 72-73
    • Diago, M.1    Hassanein, T.2    Rodes, J.3    Ackrill, A.M.4    Sedarati, F.5
  • 29
    • 21844452933 scopus 로고    scopus 로고
    • Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis
    • Derbala M, Amer A, Bener A, Lopez AC, Omar M, RL Ghannam M (2005) Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis. J Viral Hepat 12:380-385
    • (2005) J Viral Hepat , vol.12 , pp. 380-385
    • Derbala, M.1    Amer, A.2    Bener, A.3    Lopez, A.C.4    Omar, M.R.L.5    Ghannam, M.6
  • 32
  • 33
    • 30344452509 scopus 로고    scopus 로고
    • Sustained virologic response (SVR) in the EPIC3 trial: Week twelve virology predicts SVR in previous interferon/ribavirin treatment failures receiving PEG-Intron/Rebetol (PR) weight based dosing (WBD)
    • Poynard T, Shiff E, Terg R, Goncales F, Diago M, Reichen J, Moreno R, Bedossa P, Burroughs M, Albrecht J (2005) Sustained virologic response (SVR) in the EPIC3 trial: Week twelve virology predicts SVR in previous interferon/ribavirin treatment failures receiving PEG-Intron/Rebetol (PR) weight based dosing (WBD). J Hepatol 42(Suppl 2):40A
    • (2005) J Hepatol , vol.42 , Issue.SUPPL. 2
    • Poynard, T.1    Shiff, E.2    Terg, R.3    Goncales, F.4    Diago, M.5    Reichen, J.6    Moreno, R.7    Bedossa, P.8    Burroughs, M.9    Albrecht, J.10
  • 36
    • 12844260542 scopus 로고    scopus 로고
    • End-of-treatment (EOT) response in therapy-naive patients treated for chronic hepatitis C with viramidine in combination with pegylated interferon alfa-2a
    • Gish RG, Arora S, Nelson D, Fried M, Reddy KR, Xu Y, Peterson J, Murphy B (2004) End-of-treatment (EOT) response in therapy-naive patients treated for chronic hepatitis C with viramidine in combination with pegylated interferon alfa-2a. Hepatology 40(Suppl 1):388A
    • (2004) Hepatology , vol.40 , Issue.SUPPL. 1
    • Gish, R.G.1    Arora, S.2    Nelson, D.3    Fried, M.4    Reddy, K.R.5    Xu, Y.6    Peterson, J.7    Murphy, B.8
  • 37
    • 30344435164 scopus 로고    scopus 로고
    • Virologic response and safety outcomes in therapy-naive patients treated for chronic hepatitis C with viramidine in combination with pegylated interferon alfa-2a
    • Gish RG, Nelson D, Arora S, Fried MW, Reddy KR, Xu Y, Murphy B (2005) Virologic response and safety outcomes in therapy-naive patients treated for chronic hepatitis C with viramidine in combination with pegylated interferon alfa-2a. J Hepatol 42(Suppl 2):39A
    • (2005) J Hepatol , vol.42 , Issue.SUPPL. 2
    • Gish, R.G.1    Nelson, D.2    Arora, S.3    Fried, M.W.4    Reddy, K.R.5    Xu, Y.6    Murphy, B.7
  • 38
    • 33644763746 scopus 로고    scopus 로고
    • Successful retreatment of chronic hepatitis C patients with a nonresponse to standard interferon/ribavirin using daily consensus interferon and ribavirin
    • Kaiser S, Hass H, Gregor M (2004) Successful retreatment of chronic hepatitis C patients with a nonresponse to standard interferon/ribavirin using daily consensus interferon and ribavirin. Hepatology 40(Suppl 1):240A
    • (2004) Hepatology , vol.40 , Issue.SUPPL. 1
    • Kaiser, S.1    Hass, H.2    Gregor, M.3
  • 39
    • 14844316890 scopus 로고    scopus 로고
    • Colchicine versus PEG-Intron long term (COPILOT) trial: Interim analysis of clinical outcomes at year 2
    • Afdhal N, Freilich B, Levine R, Black M, Brown R, Monsour H, O'Brien M, Brass C (2004) Colchicine versus PEG-Intron long term (COPILOT) trial: interim analysis of clinical outcomes at year 2. Hepatology 40(Suppl 1):239A
    • (2004) Hepatology , vol.40 , Issue.SUPPL. 1
    • Afdhal, N.1    Freilich, B.2    Levine, R.3    Black, M.4    Brown, R.5    Monsour, H.6    O'Brien, M.7    Brass, C.8
  • 40
    • 22044454893 scopus 로고    scopus 로고
    • Peginterferon alfa-2a (40 kD) and ribavirin in patients infected with HCV genotype 1 who failed to respond to interferon and ribavirin: Final results of the Spanish high-dose induction pilot trial
    • Diago M, Romero-Gomez M, Crespo J, Olveira A, Perez R, Barcena R, Sanchez-Tapias JM, Munoz SJ (2004) Peginterferon alfa-2a (40 kD) and ribavirin in patients infected with HCV genotype 1 who failed to respond to interferon and ribavirin: Final results of the Spanish high-dose induction pilot trial. Hepatology 40(Suppl 1):389A
    • (2004) Hepatology , vol.40 , Issue.SUPPL. 1
    • Diago, M.1    Romero-Gomez, M.2    Crespo, J.3    Olveira, A.4    Perez, R.5    Barcena, R.6    Sanchez-Tapias, J.M.7    Munoz, S.J.8
  • 44
    • 10644264391 scopus 로고    scopus 로고
    • Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study
    • Dalgard O, Bjoro K, Hellum KB, Myrvang B, Ritland S, Skaug K, Raknerud N, Bell H (2004) Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study. Hepatology 40:1260-1265
    • (2004) Hepatology , vol.40 , pp. 1260-1265
    • Dalgard, O.1    Bjoro, K.2    Hellum, K.B.3    Myrvang, B.4    Ritland, S.5    Skaug, K.6    Raknerud, N.7    Bell, H.8
  • 46
    • 33847413116 scopus 로고    scopus 로고
    • Randomized multicenter study comparing 16 vs. 24 weeks of combination therapy with peginterferon alfa-2a plus ribavirin in patients chronically infected with HCV genotype 2 or 3
    • (in press)
    • von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, Bergk A, Bernsmeier C, Zeuzem S (2005) Randomized multicenter study comparing 16 vs. 24 weeks of combination therapy with peginterferon alfa-2a plus ribavirin in patients chronically infected with HCV genotype 2 or 3. Gastroenterology (in press)
    • (2005) Gastroenterology
    • von Wagner, M.1    Huber, M.2    Berg, T.3    Hinrichsen, H.4    Rasenack, J.5    Heintges, T.6    Bergk, A.7    Bernsmeier, C.8    Zeuzem, S.9
  • 49
    • 14944364772 scopus 로고    scopus 로고
    • Final phase I/II trial results for NM283, a new polymerase inhibitor for hepatitis C: Antiviral efficacy and tolerance in patients with HCV-1 infection, including previous interferon failures
    • Afdhal N, Godofsky E, Dienstag J, Rustgi V, Schick L, McEniry D, Zhou XJ, Chao G, Fang C, Fielman B, Myers M, Brown N (2004) Final phase I/II trial results for NM283, a new polymerase inhibitor for hepatitis C: antiviral efficacy and tolerance in patients with HCV-1 infection, including previous interferon failures. Hepatology 40(Suppl 1):726A
    • (2004) Hepatology , vol.40 , Issue.SUPPL. 1
    • Afdhal, N.1    Godofsky, E.2    Dienstag, J.3    Rustgi, V.4    Schick, L.5    McEniry, D.6    Zhou, X.J.7    Chao, G.8    Fang, C.9    Fielman, B.10    Myers, M.11    Brown, N.12
  • 50
    • 0033965331 scopus 로고    scopus 로고
    • Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group
    • Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J (2000) Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 31:211-218
    • (2000) Hepatology , vol.31 , pp. 211-218
    • Poynard, T.1    McHutchison, J.2    Goodman, Z.3    Ling, M.H.4    Albrecht, J.5
  • 52
    • 0041822106 scopus 로고    scopus 로고
    • Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C
    • Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J (2003) Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 38:645-652
    • (2003) Hepatology , vol.38 , pp. 645-652
    • Davis, G.L.1    Wong, J.B.2    McHutchison, J.G.3    Manns, M.P.4    Harvey, J.5    Albrecht, J.6
  • 53
    • 0033802570 scopus 로고    scopus 로고
    • Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays
    • Sarrazin C, Teuber G, Kokka R, Rabenau H, Zeuzem S (2000) Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays. Hepatology 32:818-823
    • (2000) Hepatology , vol.32 , pp. 818-823
    • Sarrazin, C.1    Teuber, G.2    Kokka, R.3    Rabenau, H.4    Zeuzem, S.5
  • 54
    • 14844296985 scopus 로고    scopus 로고
    • Highly sensitive HCV RNA detection assays for decision of treatment (dis)continuation in patients with chronic hepatitis C
    • Mihm U, Kronenberger B, Hofmann WP, Zeuzem S, Sarrazin C (2004) Highly sensitive HCV RNA detection assays for decision of treatment (dis)continuation in patients with chronic hepatitis C. J Hepatol 42(4):605-606
    • (2004) J Hepatol , vol.42 , Issue.4 , pp. 605-606
    • Mihm, U.1    Kronenberger, B.2    Hofmann, W.P.3    Zeuzem, S.4    Sarrazin, C.5
  • 55
    • 14844292907 scopus 로고    scopus 로고
    • Evaluation of a new, highly sensitive, real time PCR based assay for quantification of HCV RNA
    • Sarrazin C, Gärtner B, Welker M, Traver S, Zeuzem S (2004) Evaluation of a new, highly sensitive, real time PCR based assay for quantification of HCV RNA. J Hepatol 40(Suppl 1):150A
    • (2004) J Hepatol , vol.40 , Issue.SUPPL. 1
    • Sarrazin, C.1    Gärtner, B.2    Welker, M.3    Traver, S.4    Zeuzem, S.5
  • 56
    • 0036175978 scopus 로고    scopus 로고
    • Quantitation of hepatitis C virus RNA by third generation branched DNA-based signal amplification assay
    • Ross RS, Viazov S, Sarr S, Hoffmann S, Kramer A, Roggendorf M (2002) Quantitation of hepatitis C virus RNA by third generation branched DNA-based signal amplification assay. J Virol Methods 101:159-168
    • (2002) J Virol Methods , vol.101 , pp. 159-168
    • Ross, R.S.1    Viazov, S.2    Sarr, S.3    Hoffmann, S.4    Kramer, A.5    Roggendorf, M.6
  • 59
    • 13244249842 scopus 로고    scopus 로고
    • Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression
    • Kraus MR, Schafer A, Al Taie O, Scheurlen M (2005) Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. J Viral Hepat 12:96-100
    • (2005) J Viral Hepat , vol.12 , pp. 96-100
    • Kraus, M.R.1    Schafer, A.2    Al Taie, O.3    Scheurlen, M.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.